CL2021000516A1 - Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) - Google Patents

Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)

Info

Publication number
CL2021000516A1
CL2021000516A1 CL2021000516A CL2021000516A CL2021000516A1 CL 2021000516 A1 CL2021000516 A1 CL 2021000516A1 CL 2021000516 A CL2021000516 A CL 2021000516A CL 2021000516 A CL2021000516 A CL 2021000516A CL 2021000516 A1 CL2021000516 A1 CL 2021000516A1
Authority
CL
Chile
Prior art keywords
antibodies
tau
encode
fragments
vector
Prior art date
Application number
CL2021000516A
Other languages
English (en)
Inventor
Malcolm Ian Roberts
James Martin Staddon
Silva Hettihewage Alfred Rohan De
Jared Spidel
Hirofumi Aoyagi
Shigeru Akasofu
Yutaka Hashizume
Kishan Agarwala
Original Assignee
Eisai R&D Man Co Ltd
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Ucl Business Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2021000516A1 publication Critical patent/CL2021000516A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas.
CL2021000516A 2017-10-16 2021-03-02 Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) CL2021000516A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572910P 2017-10-16 2017-10-16
US201762577011P 2017-10-25 2017-10-25
US201862697034P 2018-07-12 2018-07-12

Publications (1)

Publication Number Publication Date
CL2021000516A1 true CL2021000516A1 (es) 2021-09-24

Family

ID=64100697

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020001003A CL2020001003A1 (es) 2017-10-16 2020-04-15 Anticuerpos anti-tau y uso de los mismos.
CL2021000517A CL2021000517A1 (es) 2017-10-16 2021-03-02 Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
CL2021000516A CL2021000516A1 (es) 2017-10-16 2021-03-02 Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2020001003A CL2020001003A1 (es) 2017-10-16 2020-04-15 Anticuerpos anti-tau y uso de los mismos.
CL2021000517A CL2021000517A1 (es) 2017-10-16 2021-03-02 Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)

Country Status (21)

Country Link
US (4) US10829547B2 (es)
EP (1) EP3697814A1 (es)
JP (2) JP6851549B2 (es)
KR (2) KR20200058480A (es)
CN (1) CN111630064B (es)
AU (1) AU2018352308B2 (es)
BR (1) BR112020007536A2 (es)
CA (1) CA3077247A1 (es)
CL (3) CL2020001003A1 (es)
CO (1) CO2020005981A2 (es)
IL (2) IL273832B (es)
JO (1) JOP20200074A1 (es)
MA (1) MA50397A (es)
MX (1) MX2020003857A (es)
PE (2) PE20212088A1 (es)
PH (2) PH12020551216A1 (es)
SG (1) SG11202003392VA (es)
TW (3) TWI853617B (es)
UA (1) UA129617C2 (es)
WO (1) WO2019077500A1 (es)
ZA (1) ZA202001548B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2766762T3 (es) 2013-03-13 2020-06-15 Prothena Biosciences Ltd Inmunoterapia contra Tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
IL270375B2 (en) 2017-05-02 2024-12-01 Prothena Biosciences Ltd Antibodies recognizing tau
PE20212088A1 (es) * 2017-10-16 2021-11-04 Eisai Randd Man Co Ltd Anticuerpos anti-tau y uso de los mismos
CN113544149B (zh) 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
WO2021173307A1 (en) * 2020-02-25 2021-09-02 Gensun Biopharma Inc. Trispecific t cell engagers
US20220064271A1 (en) * 2020-09-01 2022-03-03 Washington University Methods for treating tauopathies
US20230374063A1 (en) * 2020-10-02 2023-11-23 Eli Lilly And Company Methods for reducing host cell protein content in protein purification processes
JP2024525559A (ja) 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
AU2022381556A1 (en) 2021-11-03 2024-05-02 Eisai R&D Management Co., Ltd. Anti-tau antibody compositions, dosage forms, and methods
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023111618A1 (en) 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
CA3242280A1 (en) 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023149970A1 (en) 2022-02-02 2023-08-10 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
TW202428602A (zh) 2022-09-15 2024-07-16 美商航海家醫療公司 Ｔａｕ結合化合物
CN120202218A (zh) 2022-11-28 2025-06-24 卫材R&D管理有限公司 使用tau PET水平的治疗方法
WO2024254542A1 (en) 2023-06-09 2024-12-12 Eisai R&D Management Co., Ltd. Methods of treatment using an anti-abeta protofibril antibody
WO2025019457A1 (en) 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2008338313B2 (en) 2007-12-18 2014-01-16 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA3120504A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2987807A3 (en) 2010-10-07 2016-06-01 AC Immune S.A. Antibodies recognising phospho-tau
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
CA2829223A1 (en) 2011-03-11 2012-09-20 Beka Solomon Method for treating neurodegenerative tauopathy
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
TR201800669T4 (tr) * 2011-09-19 2018-03-21 Axon Neuroscience Se Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇
RS59024B1 (sr) 2011-12-20 2019-08-30 Janssen Biotech Inc Anti-phf-tau antitela i njihove upotrebe
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
TWI777183B (zh) 2012-05-31 2022-09-11 公立大學法人大阪市立大學 失智症治療劑或預防劑
SG11201408626YA (en) * 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
BR112015003326A2 (pt) 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
AU2013328881B2 (en) 2012-10-12 2018-03-15 Arizona Board Of Regents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9910048B2 (en) 2012-12-03 2018-03-06 Washington University Method for detection of aggregates in biological samples
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
KR102234324B1 (ko) 2012-12-21 2021-03-31 바이오젠 엠에이 인코포레이티드 인간 항-타우 항체
ES2766762T3 (es) 2013-03-13 2020-06-15 Prothena Biosciences Ltd Inmunoterapia contra Tau
US9598485B2 (en) 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
SMT202000401T1 (it) 2013-06-10 2020-11-10 Ipierian Inc Metodi di trattamento di una taupatia
GB201312226D0 (en) 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
KR20160138268A (ko) 2014-05-07 2016-12-02 가부시키가이샤 무라타 세이사쿠쇼 탄성표면파 장치
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
AU2015279089B2 (en) * 2014-06-26 2021-01-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
DE102014013571A1 (de) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
SG11201703237VA (en) * 2014-11-19 2017-06-29 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
WO2016086033A2 (en) 2014-11-25 2016-06-02 Abbott Diabetes Care Inc. Analyte monitoring systems and related test and monitoring methods
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
CA2977648C (en) 2015-02-24 2024-01-02 Rpeptide, Llc Anti-tau antibodies
JO3576B1 (ar) * 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
TWI790642B (zh) 2015-06-05 2023-01-21 美商建南德克公司 抗-tau抗體及使用方法
CN107849104B (zh) 2015-07-06 2021-08-27 Ucb生物制药有限责任公司 Tau结合抗体
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US9704904B2 (en) * 2015-08-27 2017-07-11 Taiwan Semiconductor Manufacturing Company, Ltd. Deep trench isolation structures and methods of forming same
US20190194345A1 (en) 2015-10-05 2019-06-27 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
AU2017295608B2 (en) 2016-07-12 2024-01-04 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
EP3583123A1 (en) * 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
IL270375B2 (en) * 2017-05-02 2024-12-01 Prothena Biosciences Ltd Antibodies recognizing tau
PE20212088A1 (es) * 2017-10-16 2021-11-04 Eisai Randd Man Co Ltd Anticuerpos anti-tau y uso de los mismos

Also Published As

Publication number Publication date
RU2020115817A3 (es) 2022-04-08
BR112020007536A2 (pt) 2020-09-29
ZA202001548B (en) 2021-10-27
AU2018352308B2 (en) 2025-06-05
PE20210115A1 (es) 2021-01-19
SG11202003392VA (en) 2020-05-28
TW201927817A (zh) 2019-07-16
CL2021000517A1 (es) 2021-09-24
US20210024622A1 (en) 2021-01-28
KR102225178B1 (ko) 2021-03-10
JP2021097698A (ja) 2021-07-01
PH12020550243A1 (en) 2021-02-15
US20190112364A1 (en) 2019-04-18
MX2020003857A (es) 2021-01-08
TWI853617B (zh) 2024-08-21
JP7223794B2 (ja) 2023-02-16
CN111630064B (zh) 2023-06-27
PE20212088A1 (es) 2021-11-04
AU2018352308A1 (en) 2020-03-19
KR20200058480A (ko) 2020-05-27
US11578120B2 (en) 2023-02-14
EP3697814A1 (en) 2020-08-26
RU2020115817A (ru) 2021-11-18
US20190112365A1 (en) 2019-04-18
US10829547B2 (en) 2020-11-10
CN111630064A (zh) 2020-09-04
TW202340244A (zh) 2023-10-16
IL290783A (en) 2022-04-01
CA3077247A1 (en) 2019-04-25
US10358485B2 (en) 2019-07-23
JOP20200074A1 (ar) 2020-04-30
CL2020001003A1 (es) 2020-10-02
TWI809562B (zh) 2023-07-21
JP2020536534A (ja) 2020-12-17
WO2019077500A1 (en) 2019-04-25
JP6851549B2 (ja) 2021-03-31
PH12020551216A1 (en) 2024-06-24
CO2020005981A2 (es) 2020-07-31
TW202207985A (zh) 2022-03-01
IL273832A (en) 2020-05-31
US20240034777A1 (en) 2024-02-01
KR20200051035A (ko) 2020-05-12
UA129617C2 (uk) 2025-06-18
MA50397A (fr) 2020-08-26
TWI750419B (zh) 2021-12-21
IL273832B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
CL2021000516A1 (es) Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
AR109276A1 (es) ANTICUERPOS ANTI-hCTLA 4
AR115389A1 (es) Anticuerpo antagonista de cd73
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
CL2019003627A1 (es) Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628)
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
MX2020009394A (es) Anticuerpos anti-cd73 y métodos de uso de los mismos.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
MX383464B (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
CL2019001434A1 (es) Proteínas de unión a antígeno que se unen al receptor de leptina. (divisional solicitud 201800946)
CR20180175A (es) Anticuerpos anti-cd19 humano con alta afinidad
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
MX375049B (es) Proteinas especificas novedosas para pioverdina y pioquelina.
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)